APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nanotechnology-based Drug Delivery

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nanotechnology-based Drug Delivery Market Analysis and Forecast 2026-2032

4 March 2026193 pages

Choose your research edition.

Industry ResearchNanotechnology-based Drug Delivery Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Nanotechnology-based Drug Delivery Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Nanotechnology-based Drug Delivery Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nanotechnology-based Drug Delivery Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Nanotechnology-based Drug Delivery Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Nanotechnology-based Drug Delivery market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nanotechnology-based Drug Delivery is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nanotechnology-based Drug Delivery is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nanotechnology-based Drug Delivery is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nanotechnology-based Drug Delivery is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nanotechnology-based Drug Delivery include AbbVie Inc., BlueWillow Biologics Inc., Camurus AB, Celgene, lnc., Cristal Therapeutics, EyePoint Pharmaceuticals and Johnson and Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nanotechnology-based Drug Delivery, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nanotechnology-based Drug Delivery, also provides the revenue of main regions and countries. Of the upcoming market potential for Nanotechnology-based Drug Delivery, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nanotechnology-based Drug Delivery revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nanotechnology-based Drug Delivery market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nanotechnology-based Drug Delivery revenue, projected growth trends, production technology, application and end-user industry.

Nanotechnology-based Drug Delivery Segment by Company

AbbVie Inc.

BlueWillow Biologics Inc.

Camurus AB

Celgene, lnc.

Cristal Therapeutics

EyePoint Pharmaceuticals

Johnson and Johnson

Nanotechnology-based Drug Delivery Segment by Type

Nanocrystals

Nanoparticles

Liposomes

Micelles

Others

Nanotechnology-based Drug Delivery Segment by Application

Hospital

Research Institute

Others

Nanotechnology-based Drug Delivery Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanotechnology-based Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nanotechnology-based Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanotechnology-based Drug Delivery.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nanotechnology-based Drug Delivery in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nanotechnology-based Drug Delivery company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nanotechnology-based Drug Delivery revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nanotechnology-based Drug Delivery Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Nanocrystals Major Player Table 3. Nanoparticles Major Player Table 4. Liposomes Major Player Table 5. Micelles Major Player Table 6. Others Major Player Table 7. Global Nanotechnology-based Drug Delivery Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Player Table 9. Research Institute Major Player Table 10. Others Major Player Table 11. Nanotechnology-based Drug Delivery Industry Trends Table 12. Nanotechnology-based Drug Delivery Industry Drivers Table 13. Nanotechnology-based Drug Delivery Industry Opportunities and Challenges Table 14. Nanotechnology-based Drug Delivery Industry Restraints Table 15. Global Nanotechnology-based Drug Delivery Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nanotechnology-based Drug Delivery Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nanotechnology-based Drug Delivery Market Share by Region (2021-2026) Table 18. Global Nanotechnology-based Drug Delivery Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nanotechnology-based Drug Delivery Market Share by Region (2027-2032) Table 20. Global Nanotechnology-based Drug Delivery Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nanotechnology-based Drug Delivery Revenue Market Share by Players (2021-2026) Table 22. Global Nanotechnology-based Drug Delivery Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nanotechnology-based Drug Delivery Key Players Headquarters & Area Served Table 24. Global Nanotechnology-based Drug Delivery Players, Product Type & Application Table 25. Global Nanotechnology-based Drug Delivery Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nanotechnology-based Drug Delivery by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nanotechnology-based Drug Delivery Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nanotechnology-based Drug Delivery Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nanotechnology-based Drug Delivery Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nanotechnology-based Drug Delivery Revenue Market Share by Type (2021-2026) Table 32. Global Nanotechnology-based Drug Delivery Revenue Market Share by Type (2027-2032) Table 33. Global Nanotechnology-based Drug Delivery Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nanotechnology-based Drug Delivery Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nanotechnology-based Drug Delivery Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nanotechnology-based Drug Delivery Revenue Market Share by Application (2021-2026) Table 37. Global Nanotechnology-based Drug Delivery Revenue Market Share by Application (2027-2032) Table 38. AbbVie Inc. Company Information Table 39. AbbVie Inc. Business Overview Table 40. AbbVie Inc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. AbbVie Inc. Nanotechnology-based Drug Delivery Product Portfolio Table 42. AbbVie Inc. Recent Development Table 43. BlueWillow Biologics Inc. Company Information Table 44. BlueWillow Biologics Inc. Business Overview Table 45. BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Product Portfolio Table 47. BlueWillow Biologics Inc. Recent Development Table 48. Camurus AB Company Information Table 49. Camurus AB Business Overview Table 50. Camurus AB Nanotechnology-based Drug Delivery Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Camurus AB Nanotechnology-based Drug Delivery Product Portfolio Table 52. Camurus AB Recent Development Table 53. Celgene, lnc. Company Information Table 54. Celgene, lnc. Business Overview Table 55. Celgene, lnc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Celgene, lnc. Nanotechnology-based Drug Delivery Product Portfolio Table 57. Celgene, lnc. Recent Development Table 58. Cristal Therapeutics Company Information Table 59. Cristal Therapeutics Business Overview Table 60. Cristal Therapeutics Nanotechnology-based Drug Delivery Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Cristal Therapeutics Nanotechnology-based Drug Delivery Product Portfolio Table 62. Cristal Therapeutics Recent Development Table 63. EyePoint Pharmaceuticals Company Information Table 64. EyePoint Pharmaceuticals Business Overview Table 65. EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Product Portfolio Table 67. EyePoint Pharmaceuticals Recent Development Table 68. Johnson and Johnson Company Information Table 69. Johnson and Johnson Business Overview Table 70. Johnson and Johnson Nanotechnology-based Drug Delivery Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Johnson and Johnson Nanotechnology-based Drug Delivery Product Portfolio Table 72. Johnson and Johnson Recent Development Table 73. North America Nanotechnology-based Drug Delivery Revenue by Type (2021-2026) & (US$ Million) Table 74. North America Nanotechnology-based Drug Delivery Revenue by Type (2027-2032) & (US$ Million) Table 75. North America Nanotechnology-based Drug Delivery Revenue by Application (2021-2026) & (US$ Million) Table 76. North America Nanotechnology-based Drug Delivery Revenue by Application (2027-2032) & (US$ Million) Table 77. North America Nanotechnology-based Drug Delivery Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 78. North America Nanotechnology-based Drug Delivery Revenue by Country (2021-2026) & (US$ Million) Table 79. North America Nanotechnology-based Drug Delivery Revenue by Country (US$ Million) & (2027-2032) Table 80. Europe Nanotechnology-based Drug Delivery Revenue by Type (2021-2026) & (US$ Million) Table 81. Europe Nanotechnology-based Drug Delivery Revenue by Type (2027-2032) & (US$ Million) Table 82. Europe Nanotechnology-based Drug Delivery Revenue by Application (2021-2026) & (US$ Million) Table 83. Europe Nanotechnology-based Drug Delivery Revenue by Application (2027-2032) & (US$ Million) Table 84. Europe Nanotechnology-based Drug Delivery Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. Europe Nanotechnology-based Drug Delivery Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Nanotechnology-based Drug Delivery Revenue by Country (US$ Million) & (2027-2032) Table 87. China Nanotechnology-based Drug Delivery Revenue by Type (2021-2026) & (US$ Million) Table 88. China Nanotechnology-based Drug Delivery Revenue by Type (2027-2032) & (US$ Million) Table 89. China Nanotechnology-based Drug Delivery Revenue by Application (2021-2026) & (US$ Million) Table 90. China Nanotechnology-based Drug Delivery Revenue by Application (2027-2032) & (US$ Million) Table 91. Asia Nanotechnology-based Drug Delivery Revenue by Type (2021-2026) & (US$ Million) Table 92. Asia Nanotechnology-based Drug Delivery Revenue by Type (2027-2032) & (US$ Million) Table 93. Asia Nanotechnology-based Drug Delivery Revenue by Application (2021-2026) & (US$ Million) Table 94. Asia Nanotechnology-based Drug Delivery Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Nanotechnology-based Drug Delivery Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Asia Nanotechnology-based Drug Delivery Revenue by Region (US$ Million) & (2021-2026) Table 97. Asia Nanotechnology-based Drug Delivery Revenue by Region (US$ Million) & (2027-2032) Table 98. SAMEA Nanotechnology-based Drug Delivery Revenue by Type (2021-2026) & (US$ Million) Table 99. SAMEA Nanotechnology-based Drug Delivery Revenue by Type (2027-2032) & (US$ Million) Table 100. SAMEA Nanotechnology-based Drug Delivery Revenue by Application (2021-2026) & (US$ Million) Table 101. SAMEA Nanotechnology-based Drug Delivery Revenue by Application (2027-2032) & (US$ Million) Table 102. SAMEA Nanotechnology-based Drug Delivery Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. SAMEA Nanotechnology-based Drug Delivery Revenue by Country (2021-2026) & (US$ Million) Table 104. SAMEA Nanotechnology-based Drug Delivery Revenue by Country (US$ Million) & (2027-2032) Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Nanotechnology-based Drug Delivery Image Figure 2. Global Nanotechnology-based Drug Delivery Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nanotechnology-based Drug Delivery Market Size Share 2021 VS 2025 VS 2032 Figure 4. Nanocrystals Image Figure 5. Nanoparticles Image Figure 6. Liposomes Image Figure 7. Micelles Image Figure 8. Others Image Figure 9. Global Nanotechnology-based Drug Delivery Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Nanotechnology-based Drug Delivery Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Research Institute Image Figure 13. Others Image Figure 14. Global Nanotechnology-based Drug Delivery Market Size (US$ Million) & (2021-2032) Figure 15. Global Nanotechnology-based Drug Delivery Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nanotechnology-based Drug Delivery Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nanotechnology-based Drug Delivery Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nanotechnology-based Drug Delivery Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nanotechnology-based Drug Delivery Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nanotechnology-based Drug Delivery Revenue Market Share by Type (2021-2032) Figure 22. Global Nanotechnology-based Drug Delivery Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nanotechnology-based Drug Delivery Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nanotechnology-based Drug Delivery Revenue Market Share by Application (2021-2032) Figure 25. North America Nanotechnology-based Drug Delivery Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032) Figure 27. North America Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032) Figure 28. North America Nanotechnology-based Drug Delivery Revenue Share by Country (2021-2032) Figure 29. United States Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nanotechnology-based Drug Delivery Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032) Figure 34. Europe Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032) Figure 35. Europe Nanotechnology-based Drug Delivery Revenue Share by Country (2021-2032) Figure 36. Germany Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nanotechnology-based Drug Delivery Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032) Figure 46. China Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032) Figure 47. Asia Nanotechnology-based Drug Delivery Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032) Figure 49. Asia Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032) Figure 50. Asia Nanotechnology-based Drug Delivery Revenue Share by Region (2021-2032) Figure 51. Japan Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nanotechnology-based Drug Delivery Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032) Figure 59. SAMEA Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032) Figure 60. SAMEA Nanotechnology-based Drug Delivery Revenue Share by Country (2021-2032) Figure 61. Brazil Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nanotechnology-based Drug Delivery Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Nanocrystals
  • Nanoparticles
  • Liposomes
  • Micelles
  • Others
Applications
  • Hospital
  • Research Institute
  • Others
Companies covered
  • AbbVie Inc.
  • BlueWillow Biologics Inc.
  • Camurus AB
  • Celgene, lnc.
  • Cristal Therapeutics
  • EyePoint Pharmaceuticals
  • Johnson and Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nanotechnology-based Drug Delivery Market by Type
  3. 1.2.1 Global Nanotechnology-based Drug Delivery Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Nanocrystals
  5. 1.2.3 Nanoparticles
  6. 1.2.4 Liposomes
  7. 1.2.5 Micelles
  8. 1.2.6 Others
  9. 1.3 Nanotechnology-based Drug Delivery Market by Application
  10. 1.3.1 Global Nanotechnology-based Drug Delivery Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Research Institute
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nanotechnology-based Drug Delivery Market Dynamics
  1. 2.1 Nanotechnology-based Drug Delivery Industry Trends
  2. 2.2 Nanotechnology-based Drug Delivery Industry Drivers
  3. 2.3 Nanotechnology-based Drug Delivery Industry Opportunities and Challenges
  4. 2.4 Nanotechnology-based Drug Delivery Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nanotechnology-based Drug Delivery Market Perspective (2021-2032)
  2. 3.2 Global Nanotechnology-based Drug Delivery Growth Trends by Region
  3. 3.2.1 Global Nanotechnology-based Drug Delivery Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nanotechnology-based Drug Delivery Market Size by Region (2021-2026)
  5. 3.2.3 Global Nanotechnology-based Drug Delivery Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nanotechnology-based Drug Delivery Revenue by Players
  2. 4.1.1 Global Nanotechnology-based Drug Delivery Revenue by Players (2021-2026)
  3. 4.1.2 Global Nanotechnology-based Drug Delivery Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nanotechnology-based Drug Delivery Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nanotechnology-based Drug Delivery Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nanotechnology-based Drug Delivery Key Players Headquarters & Area Served
  7. 4.4 Global Nanotechnology-based Drug Delivery Players, Product Type & Application
  8. 4.5 Global Nanotechnology-based Drug Delivery Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nanotechnology-based Drug Delivery Market CR5 and HHI
  11. 4.6.3 2025 Nanotechnology-based Drug Delivery Tier 1, Tier 2, and Tier 3
5 Nanotechnology-based Drug Delivery Market Size by Type
  1. 5.1 Global Nanotechnology-based Drug Delivery Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nanotechnology-based Drug Delivery Revenue by Type (2021-2032)
  3. 5.3 Global Nanotechnology-based Drug Delivery Revenue Market Share by Type (2021-2032)
6 Nanotechnology-based Drug Delivery Market Size by Application
  1. 6.1 Global Nanotechnology-based Drug Delivery Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nanotechnology-based Drug Delivery Revenue by Application (2021-2032)
  3. 6.3 Global Nanotechnology-based Drug Delivery Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AbbVie Inc.
  2. 7.1.1 AbbVie Inc. Company Information
  3. 7.1.2 AbbVie Inc. Business Overview
  4. 7.1.3 AbbVie Inc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AbbVie Inc. Nanotechnology-based Drug Delivery Product Portfolio
  6. 7.1.5 AbbVie Inc. Recent Developments
  7. 7.2 BlueWillow Biologics Inc.
  8. 7.2.1 BlueWillow Biologics Inc. Company Information
  9. 7.2.2 BlueWillow Biologics Inc. Business Overview
  10. 7.2.3 BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Product Portfolio
  12. 7.2.5 BlueWillow Biologics Inc. Recent Developments
  13. 7.3 Camurus AB
  14. 7.3.1 Camurus AB Company Information
  15. 7.3.2 Camurus AB Business Overview
  16. 7.3.3 Camurus AB Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Camurus AB Nanotechnology-based Drug Delivery Product Portfolio
  18. 7.3.5 Camurus AB Recent Developments
  19. 7.4 Celgene, lnc.
  20. 7.4.1 Celgene, lnc. Company Information
  21. 7.4.2 Celgene, lnc. Business Overview
  22. 7.4.3 Celgene, lnc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Celgene, lnc. Nanotechnology-based Drug Delivery Product Portfolio
  24. 7.4.5 Celgene, lnc. Recent Developments
  25. 7.5 Cristal Therapeutics
  26. 7.5.1 Cristal Therapeutics Company Information
  27. 7.5.2 Cristal Therapeutics Business Overview
  28. 7.5.3 Cristal Therapeutics Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Cristal Therapeutics Nanotechnology-based Drug Delivery Product Portfolio
  30. 7.5.5 Cristal Therapeutics Recent Developments
  31. 7.6 EyePoint Pharmaceuticals
  32. 7.6.1 EyePoint Pharmaceuticals Company Information
  33. 7.6.2 EyePoint Pharmaceuticals Business Overview
  34. 7.6.3 EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  35. 7.6.4 EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Product Portfolio
  36. 7.6.5 EyePoint Pharmaceuticals Recent Developments
  37. 7.7 Johnson and Johnson
  38. 7.7.1 Johnson and Johnson Company Information
  39. 7.7.2 Johnson and Johnson Business Overview
  40. 7.7.3 Johnson and Johnson Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Johnson and Johnson Nanotechnology-based Drug Delivery Product Portfolio
  42. 7.7.5 Johnson and Johnson Recent Developments
8 North America
  1. 8.1 North America Nanotechnology-based Drug Delivery Revenue (2021-2032)
  2. 8.2 North America Nanotechnology-based Drug Delivery Revenue by Type (2021-2032)
  3. 8.2.1 North America Nanotechnology-based Drug Delivery Revenue by Type (2021-2026)
  4. 8.2.2 North America Nanotechnology-based Drug Delivery Revenue by Type (2027-2032)
  5. 8.3 North America Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032)
  6. 8.4 North America Nanotechnology-based Drug Delivery Revenue by Application (2021-2032)
  7. 8.4.1 North America Nanotechnology-based Drug Delivery Revenue by Application (2021-2026)
  8. 8.4.2 North America Nanotechnology-based Drug Delivery Revenue by Application (2027-2032)
  9. 8.5 North America Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032)
  10. 8.6 North America Nanotechnology-based Drug Delivery Revenue by Country
  11. 8.6.1 North America Nanotechnology-based Drug Delivery Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nanotechnology-based Drug Delivery Revenue by Country (2021-2026)
  13. 8.6.3 North America Nanotechnology-based Drug Delivery Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Nanotechnology-based Drug Delivery Revenue (2021-2032)
  2. 9.2 Europe Nanotechnology-based Drug Delivery Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nanotechnology-based Drug Delivery Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nanotechnology-based Drug Delivery Revenue by Type (2027-2032)
  5. 9.3 Europe Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nanotechnology-based Drug Delivery Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nanotechnology-based Drug Delivery Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nanotechnology-based Drug Delivery Revenue by Application (2027-2032)
  9. 9.5 Europe Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nanotechnology-based Drug Delivery Revenue by Country
  11. 9.6.1 Europe Nanotechnology-based Drug Delivery Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nanotechnology-based Drug Delivery Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nanotechnology-based Drug Delivery Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Nanotechnology-based Drug Delivery Revenue (2021-2032)
  2. 10.2 China Nanotechnology-based Drug Delivery Revenue by Type (2021-2032)
  3. 10.2.1 China Nanotechnology-based Drug Delivery Revenue by Type (2021-2026)
  4. 10.2.2 China Nanotechnology-based Drug Delivery Revenue by Type (2027-2032)
  5. 10.3 China Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032)
  6. 10.4 China Nanotechnology-based Drug Delivery Revenue by Application (2021-2032)
  7. 10.4.1 China Nanotechnology-based Drug Delivery Revenue by Application (2021-2026)
  8. 10.4.2 China Nanotechnology-based Drug Delivery Revenue by Application (2027-2032)
  9. 10.5 China Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nanotechnology-based Drug Delivery Revenue (2021-2032)
  2. 11.2 Asia Nanotechnology-based Drug Delivery Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nanotechnology-based Drug Delivery Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nanotechnology-based Drug Delivery Revenue by Type (2027-2032)
  5. 11.3 Asia Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nanotechnology-based Drug Delivery Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nanotechnology-based Drug Delivery Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nanotechnology-based Drug Delivery Revenue by Application (2027-2032)
  9. 11.5 Asia Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nanotechnology-based Drug Delivery Revenue by Country
  11. 11.6.1 Asia Nanotechnology-based Drug Delivery Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nanotechnology-based Drug Delivery Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nanotechnology-based Drug Delivery Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nanotechnology-based Drug Delivery Revenue (2021-2032)
  2. 12.2 SAMEA Nanotechnology-based Drug Delivery Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nanotechnology-based Drug Delivery Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nanotechnology-based Drug Delivery Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nanotechnology-based Drug Delivery Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nanotechnology-based Drug Delivery Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nanotechnology-based Drug Delivery Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nanotechnology-based Drug Delivery Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nanotechnology-based Drug Delivery Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nanotechnology-based Drug Delivery Revenue by Country
  11. 12.6.1 SAMEA Nanotechnology-based Drug Delivery Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nanotechnology-based Drug Delivery Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nanotechnology-based Drug Delivery Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst